There were a lot of companies that jumped to action last year in the fight against the SARS-CoV-2 virus. In that latter category, one company proved it has a business model to succeed long after the pandemic ends -- assuming it ever does. Fulgent Genetics (NASDAQ: FLGT) burst onto the scene when the Food and Drug Administration (FDA) approved its test for detecting COVID-19 in June 2020.
Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting